“…The reason why patients with pretreatment leukocytosis/neutrophilia are at high risk of developing distant relapse remains unclear, but the present results are consistent with the findings of our previous study in which pretreatment leukocytosis/neutrophilia were found to be independent predictors of survival among cervical cancer patients . In the current analysis, tumor size, reported to be a predictor of distant relapse in a previous study, was not found to be a significant prognostic factor. This discrepancy might be explained by the relatively small sample size of the current study or racial differences.…”
Section: Discussionsupporting
confidence: 92%
“…A previous study showed that nodal status is a significant predictor of distant relapse after definitive RT in LACC patients . Other studies have suggested that the size of the primary tumor and advanced clinical stage are predictors of distant relapse in such patients …”
Roughly 28% of patients with FIGO stage IIB-IVA cervical cancer developed distant relapse after definitive RT. Pelvic lymph node metastasis and pretreatment leukocytosis/neutrophilia are independent predictors of distant relapse.
“…The reason why patients with pretreatment leukocytosis/neutrophilia are at high risk of developing distant relapse remains unclear, but the present results are consistent with the findings of our previous study in which pretreatment leukocytosis/neutrophilia were found to be independent predictors of survival among cervical cancer patients . In the current analysis, tumor size, reported to be a predictor of distant relapse in a previous study, was not found to be a significant prognostic factor. This discrepancy might be explained by the relatively small sample size of the current study or racial differences.…”
Section: Discussionsupporting
confidence: 92%
“…A previous study showed that nodal status is a significant predictor of distant relapse after definitive RT in LACC patients . Other studies have suggested that the size of the primary tumor and advanced clinical stage are predictors of distant relapse in such patients …”
Roughly 28% of patients with FIGO stage IIB-IVA cervical cancer developed distant relapse after definitive RT. Pelvic lymph node metastasis and pretreatment leukocytosis/neutrophilia are independent predictors of distant relapse.
“…Since at some levels of the paraaortic region the small bowel closely surrounded the target volume, it was inevitable that some parts of the small intestine received a dose equal or close to the target dose. In the literature, a variable increase in complications is observed in patients receiving over 50 Gy [19,24], although in 1 study [26] doses ranging from 56 to 61 Gy were not significantly more hazardous than in case of pelvis irradiation only.…”
Section: Discussionmentioning
confidence: 98%
“…In fact, prophylactic para-aortic irradiation is an issue which is currently unresolved. However, Rotman et al [26] did demonstrate a benefit in overall and distant metastasis-free survival in patients with Stage Ib (bulky), IIa and IIb. Also after follow-up of 5 years [7,27] overall survival was significantly better for those treated with extended fields compared to those treated with pelvic radiation (55% vs 44%; p = 0.02, respectively).…”
The small bowel dose can be significantly reduced with 3D treatment planning, particularly if a pedicled omentoplasty is performed. This allows dose escalation to the tumor region without unacceptable toxicity for the small bowel.
“…9, 11, 12) has led to new ways of treatment strategies. However, neither a split-course technique (28) applying 60 Gy, nor the reduction of the total dose (9,21,29,30) has had the expected success.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations鈥揷itations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.